February 16, 2023
NX Prenatal Announced as Founding Member of New Alliance for Prenatal Health Equity
NX Prenatal Inc. today announced a partnership with the Louisville-based Health Equity Innovation Hub (the “Hub”) to establish
a new Alliance for Prenatal Health Equity. The Hub is a funded initiative of Humana Inc., the Humana Foundation, and the University of Louisville established to advance health equity and improve health outcomes for marginalized populations in Louisville and communities around the world.
January 23, 2023
JNJ.com: 2 Big Ideas to Help Lower the Risk of Maternal-Fetal Complications in BIPOC Women
Women from historically underrepresented communities have a higher risk of pregnancy complications. So Johnson & Johnson Innovation challenged researchers to propose potential solutions that aim to address this troubling healthcare disparity. These awardees just might be the game changers.
January 18, 2023
NX Prenatal Announces Addition of Dr. Robert Bonebrake to Strategic Advisory Board
NX Prenatal Inc. today announced that Robert G. Bonebrake, MD, FACOG has joined its Strategic Advisory Board. Dr. Bonebrake is a partner with Perinatal Associates at The Methodist Perinatal Center at Nebraska Methodist Women’s Hospital. He is also a Clinical Associate Professor in the Department of Obstetrics and Gynecology at the University of Nebraska Medical Center, and currently serves as the President of the Medical Staff for Nebraska Methodist Health system and is the past Chair of the Department of Maternal and Child for Methodist Health System. Dr. Bonebrake also serves as the Chair of the State of Nebraska Maternal Mortality Committee and the Co- Medical Director of the Nebraska Perinatal Quality Improvement Collaborative. He has numerous publications and has many invited presentations, with special emphasis on antenatal diagnosis of complications of pregnancy and delivery.
January 5, 2023
NX Prenatal Announces Breakthrough Findings for the Detection of Placenta Accreta
NX Prenatal Inc. and its collaborators have published the results of a new clinical study demonstrating the utility of its proprietary exosome-based liquid biopsy platform for the detection of biomarkers that have the potential to identify pregnant patients with Placenta Accreta Spectrum (PAS). There are no current blood tests for this condition which is a significant contributor to maternal morbidity and mortality. Pregnant moms that have had prior C-Sections or other gynecologic surgical procedures are at heightened risk for PAS. The current imaging techniques are estimated to capture only one-third to one-half of cases (primarily high grade). The findings were published in Scientific Reports.
November 17, 2022
World Prematurity Day 2022: Extracellular Vesicles as Predictors of Premature Birth
In the search for biomarkers of premature birth, EVs are showing promise. EVs are released by all cells, including those of the placenta, allowing for peripheral sampling of placental biomarkers. EVs also protect their cargo which is delivered to target cells, providing a source of circulating biomarkers which would otherwise be degraded. These advantages of EVs as biomarker sources has driven a surge of research into EV biomarkers for preterm birth. Leading the way in this space is NX Prenatal, a company developing diagnostic tests to predict preterm birth and other pregnancy complications based on EVs.
November 1, 2022
NX Prenatal Named as an Awardee in Maternal-Fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity
NX Prenatal Inc. has been selected as an awardee of the Maternal-fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity. Launched by Johnson & Johnson Innovation in collaboration with the Office of the Chief Medical Officer of The Johnson & Johnson Family of Companies (OCMO) Health of Women team, together with The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), the QuickFire Challenge award will include grant funding and mentorship from experts to help catalyze innovations directed toward the prevention of adverse pregnancy outcomes.
April 1, 2021
NX Prenatal Announces Initiation of a Clinical Study for the Detection of Placenta Accreta
NX Prenatal Inc. announced today that it is a sponsor and collaborator for an upcoming clinical study whereby its NeXosome® liquid biopsy platform will be key in the detection of biomarkers that can identify pregnant patients with Placenta Accreta Spectrum (PAS). Pregnant moms that have had prior C-sections, or IVF-assisted conception, or prior D&C procedures are known to be in elevated risk categories for PAS, but there is no current blood test that can help identify which of those moms may experience this life-threatening condition.
January 27, 2021
NX Prenatal Expands Leading Patent Position in Exosome-Based Liquid Biopsy Tests in Maternal- Fetal Medicine
NX Prenatal Inc. today announced that it has achieved new patent issuances in both the United States and Europe for its exosome-based liquid biopsy tests for the early identification of pregnant mothers at elevated risk for spontaneous preterm birth. NX Prenatal controls worldwide rights to a portfolio of more than three dozen pending and issued patents that feature the earliest and most comprehensive claims related to the utilization of exosomes for the detection and management of adverse pregnancy outcomes.
October 26, 2020
NX Prenatal Announces Publication of First Trimester Exosome Liquid Biopsy Test Data for Preeclampsia Risk
NX Prenatal Inc. today announced the publication of new data demonstrating that exosome-associated protein biomarkers derived from first trimester maternal plasma are key in predicting the overall risk of developing Preeclampsia, and further indicate the ability to identify distinct subtypes of pathophysiology and predict severity of clinical presentation among Preeclampsia patients.
The peer-reviewed study of asymptomatic pregnant subjects was published in Scientific Reports and was conducted together with Brigham and Women’s Hospital and Thermo Fisher Scientific.
April 05, 2019
NX Prenatal and Thermo Fisher Announce Strategic Collaboration to Support Commercialization of Prenatal Tests
NX Prenatal Inc. (“NX Prenatal”) and Thermo Fisher Scientific have announced a strategic collaboration designed to expand upon integrated workflows that the companies have established to enable high volume clinical mass spec proteomic evaluation of plasma samples enriched for exosomes via the NeXosome® platform.
“Thermo Fisher is a world leader in proteomics, and its liquid chromatography-mass spectrometry (LC-MS) instrumentation is an enabling technology for the new era of personalized medicine,” commented Kevin P. Rosenblatt, MD, PhD, Chief Medical and Scientific Officer of NX Prenatal.
February 28, 2019
NX Prenatal Announces Publication of Peer-Reviewed Study in the American Journal of Obstetrics & Gynecology for Validation of First Trimester Preterm Birth Risk Biomarkers
NX Prenatal Inc., focused on development of proprietary blood-based, early warning molecular diagnostic tests for adverse pregnancy outcomes, announced today the publication of a peer-reviewed study, "Circulating Microparticle Proteins Obtained in the Late First Trimester Predict Spontaneous Preterm Birth at Less than 35 Weeks Gestation: A Panel Validation with Specific Characterization by Parity" in the American Journal of Obstetrics & Gynecology. The publication is available online: https://doi.org/10.1016/j.ajog.2019.01.220.
The findings represent the first reported multi-site validation of blood-based biomarker panels at 10-12 weeks gestation to stratify pregnant patients for the risk of preterm birth.
January 16, 2019
NX Prenatal and Milu Labs Announce Strategic Collaboration to Commercialize Exosome-Based Preterm Birth Risk Test in Asia
NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that it has entered into a strategic collaboration with Milu Labs, whose mission is to become the leading diagnostics company in Asia with a focus on maternal fetal medicine and women’s health.
“Given China’s vast population, its healthcare system wisely focuses on disease prevention and investing in early disease detection. These efforts will minimize the costs from outcomes such as preterm birth, which can bring a lifetime of medical complications,” commented Dr. Daniel Chai, co-founder & CEO of Milu Labs. “NX Prenatal’s proprietary NeXosome® liquid biopsy platform, together with sophisticated AI and bioinformatics/statistical approaches, has yielded the necessary breakthrough in this field – a blood test as early as 10-12 weeks which can stratify women at risk for preterm birth.”
November 13, 2018
Expanding Applications of NX Prenatal's Exosome-Based Diagnostics Platform Presented at Key Conferences
NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that expanding applications of its proprietary NeXosome® liquid biopsy platform were presented at recent scientific conferences.
“NX Prenatal is setting the stage for its exosome-based platform to play a significant role in identifying and monitoring for key risks in pregnancy at a time point that is actionable and has the potential to improve outcomes and drive tremendous cost from the system,” commented Gail Page, Executive Chair for NX Prenatal. “We are creating a menu of tests that will allow physicians to augment their clinical observations with biologically important molecular data for personalized care in pregnancy.”
October 24, 2018
NX Prenatal Announces Key Clinical Validation Trial of its Exosome-Based Blood Test for Preterm Birth Risk in Collaboration with Indiana University School of Medicine
HOUSTON and LOUISVILLE, Ky., Oct. 24, 2018 /PRNewswire/ -- NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that it has entered into a collaboration with Indiana University School of Medicine to further validate its early pregnancy biomarker panels that predict Spontaneous Preterm Birth (SPTB) and to further develop its biomarker panels for Preeclampsia (PE). "The collaboration builds upon published data in which NX Prenatal has demonstrated that the enrichment of exosome and microvesicle particles from maternal blood and subsequent biomarker analysis enables risk stratification of preterm birth and preeclampsia as early as 10-12 weeks into the pregnancy. This 'early detection' result has not been realized by other approaches," commented Dr. Kevin Rosenblatt, Chief Medical and Scientific Officer of NX Prenatal.
Blood samples from more than 2,300 women will be evaluated at first trimester and second trimester time points. The samples were prospectively collected at more than 20 hospitals affiliated with 8 clinical research centers across the US, including IU School of Medicine. Extensive medical data, demographic data, outcomes, and follow-up data were collected according to standardized protocols. All of the women in the study are "nulliparous," meaning they had not previously given birth, so there was no history of a preterm birth. As such, this is a low-risk population that is the most difficult for physicians to risk-stratify and manage. The size of the study will allow for the evaluation of co-risk factors like age, body mass index, nutrition and socio-economic factors.
October 16, 2018
NX Prenatal Invited to Participate in the Solebury Trout 4th Annual Private Company Showcase in New York
NX Prenatal today announced that senior management will participate in the Solebury Trout 4th Annual Private Company Showcase in New York City. The event is attended by investors focused on private, emerging stage biotech companies and co-hosted by Davis Polk, BMO, RR Donnelley and CFGI.
Event: Solebury Trout 4th Annual Private Company Showcase
Date/Time: Friday, October 19, 2018 at 1:00 pm EDT
Location: New York, NY
February 16, 2018
NX Prenatal Expands Pipeline with New Preeclampsia Biomarker Risk Assessment Data
NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that new clinical study data will be presented at the Society of Reproductive Investigation’s (SRI) 65th Annual Scientific Meeting in San Diego, California, on March 9th, 2018. The oral presentation will describe results from a study of plasma samples obtained from pregnant mothers demonstrating proteomic biomarkers that are already unique in their expression profiles at 10-12 weeks gestation among women who go on to experience preeclampsia (PE). The new study builds upon a series of previously published studies in which NX Prenatal has demonstrated that the enrichment of exosome and microvesicle particles from maternal blood and subsequent proteomic analysis enables risk stratification of spontaneous preterm birth (SPTB) in the first trimester of pregnancy.
January 08, 2018
NX Prenatal to Present at the 2018 Society for Maternal Fetal Medicine Annual Meeting in Dallas, Texas
NX Prenatal Inc., a US based molecular diagnostics company utilizing its proprietary NeXosome® technology for early warning of adverse pregnancy outcomes, announced today that data from its ongoing validation studies will be presented at the Society of Maternal Fetal Medicine’s (SMFM) annual meeting held in Dallas, TX, January 29th through February 3rd, 2018. The presentation will describe results from a multicenter study of samples obtained from 186 pregnant mothers designed to validate the performance of functional proteomic biomarker panels that are already unique in their expression profiles at 10-12 weeks gestation among women who go on to deliver spontaneously at less than 35 weeks.
April 20, 2017
NX Prenatal to Present Novel Technology at London Conference on Preterm Birth
NX Prenatal Inc. (“NX Prenatal”) today announced that its innovative technology would be presented at an upcoming conference in London, at the invitation of a Preterm Birth Working Group organized by the International Federation of Gynecology and Obstetrics (FIGO) and the March of Dimes (MOD). The FIGO/MOD Working Group consists of an international panel of experts exploring the role biomarkers could play in predicting preterm birth and other adverse pregnancy outcomes, and plans to make recommendations for the global obstetrical community.
January 19, 2017
NX Prenatal Appoints Leading Experts to Medical/Clinical Advisory Board
NX Prenatal Inc., today announced the appointment of four industry experts to its Medical/Clinical Advisory Board, including: Kevin P. Rosenblatt, MD, PhD (NX Prenatal's CMO/CSO), Mary Lake Polan, MD, PhD, MPH (Chair Emeritus of Stanford University's Dept. of Obstetrics and Gynecology, and Clinical Professor in the Dept. of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine), Daniel W. Chan, PhD, DABCC, FACB (Director of the Johns Hopkins University Biomarker Discovery and Translation Center), and Thomas McElrath, MD, PhD, FACOG (Maternal-Fetal Medicine physician, Harvard Medical School Associate Professor of Obsetrics, Gynecology and Reproductive Biology, and Director of the Preterm Birth Clinic at Brigham & Women's Hospital).
October 21, 2016
NX Prenatal Names Dr. Kevin Rosenblatt Chief Medical and Scientific Officer
NX Prenatal Inc., a privately held biotechnology company developing novel diagnostic tests in the women's health field, today announced the appointment of Kevin P. Rosenblatt, MD, PhD, as Chief Medical and Scientific Officer. In this role, Dr. Rosenblatt will bring his extensive experience in biomarker discovery, clinical proteomics, and clinical assay development to advance NXPN's proprietary pipeline of exosome-based diagnostic tests.
March 22, 2016
NX Prenatal Premature Birth Biomarker study published in prestigious American Journal of Obstetrics and Gynecology
NX Prenatal, Inc. announced today that the American Journal of Obstetrics and Gynecology (“AJOG”) published a manuscript entitled, “Evaluation of proteomic biomarkers associated with circulating microparticles as an effective means to stratify the risk of spontaneous preterm birth,” from a clinical study evaluating blood-based biomarkers in pregnant mothers. In the study, candidate biomarker panels comprised of exosome-associated proteins evaluated at week 10-12 of gestation were shown to effectively differentiate groups women who go on to deliver spontaneously at less than 34 weeks versus term delivering controls (≥ 37 weeks).
January 07, 2016
NX Prenatal research findings to be presented at the SMFM Oral Concurrent Session 1, February 4, 2016
In a blinded peer-reviewed process, the Society for Maternal Fetal Medicine has selected our study titled “Circulating microparticles as an effective means to stratify the risk of spontaneous preterm birth” for oral presentation during its upcoming 36th Annual Pregnancy Meeting in Atlanta, GA. Dr. Thomas McElrath of Brigham & Women’s Hospital will present data from this new collaborative study designed to identify functional proteomic biomarkers that are already unique in their expression profiles at 10-12 weeks gestation among women who go on to deliver spontaneously <34 weeks. The analysis of circulating microparticles (CMPs) in pregnancy is of revolutionary potential as it represents an in vivo ‘biopsy’ of active gestational tissues, with the goal of identifying dysfunctional processes long before clinical presentation of symptoms.
June 18, 2015
NX Prenatal Study Identifies Novel Proteomic Biomarkers of Spontaneous Preterm Birth from Serum-Derived Microparticles
The American Journal of Perinatology has published the results of a blinded, retrospective study of 48 asymptomatic, healthy pregnant women that demonstrates the feasibility of assessing biomarkers associated with blood based microvesicles/exosomes for spontaneous preterm birth (SPTB) risk. The study describes a new library of statistically valued biomarkers for prenatal risk assessment that were identified at week 15-17 of gestation.
May 27, 2015
Gail S. Page Joins NX Prenatal’s Board of Directors as Executive Chairperson
NX Prenatal announced today that Gail S. Page has joined the Board of Directors and will serve as Executive Chairperson. Ms. Page served as the President, CEO and Director of Vermillion, Inc. from 2006 through 2012. Under her leadership, Vermillion successfully raised over $100M in funding, as it developed and commercially launched the first proteomic IVDMIA FDA cleared blood test to help diagnose ovarian cancer. Ms. Page will be working with NX Prenatal to guide the commercial development of blood-based tests to support improved pregnancy outcomes.